1
|
Abt ER, Rashid K, Le TM, Li S, Lee HR, Lok V, Li L, Creech AL, Labora AN, Mandl HK, Lam AK, Cho A, Rezek V, Wu N, Abril-Rodriguez G, Rosser EW, Mittelman SD, Hugo W, Mehrling T, Bantia S, Ribas A, Donahue TR, Crooks GM, Wu TT, Radu CG. Purine nucleoside phosphorylase enables dual metabolic checkpoints that prevent T cell immunodeficiency and TLR7-associated autoimmunity. J Clin Invest 2022; 132:e160852. [PMID: 35653193 PMCID: PMC9374381 DOI: 10.1172/jci160852] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2022] [Accepted: 05/31/2022] [Indexed: 01/27/2023] Open
Abstract
Purine nucleoside phosphorylase (PNP) enables the breakdown and recycling of guanine nucleosides. PNP insufficiency in humans is paradoxically associated with both immunodeficiency and autoimmunity, but the mechanistic basis for these outcomes is incompletely understood. Here, we identify two immune lineage-dependent consequences of PNP inactivation dictated by distinct gene interactions. During T cell development, PNP inactivation is synthetically lethal with downregulation of the dNTP triphosphohydrolase SAMHD1. This interaction requires deoxycytidine kinase activity and is antagonized by microenvironmental deoxycytidine. In B lymphocytes and macrophages, PNP regulates Toll-like receptor 7 signaling by controlling the levels of its (deoxy)guanosine nucleoside ligands. Overriding this regulatory mechanism promotes germinal center formation in the absence of exogenous antigen and accelerates disease in a mouse model of autoimmunity. This work reveals that one purine metabolism gene protects against immunodeficiency and autoimmunity via independent mechanisms operating in distinct immune lineages and identifies PNP as a potentially novel metabolic immune checkpoint.
Collapse
Affiliation(s)
- Evan R. Abt
- Department of Molecular and Medical Pharmacology and
| | - Khalid Rashid
- Department of Molecular and Medical Pharmacology and
| | - Thuc M. Le
- Department of Molecular and Medical Pharmacology and
| | - Suwen Li
- Department of Molecular and Medical Pharmacology and
| | - Hailey R. Lee
- Department of Molecular and Medical Pharmacology and
| | - Vincent Lok
- Department of Molecular and Medical Pharmacology and
| | - Luyi Li
- Department of Surgery, UCLA, Los Angeles, California, USA
| | | | | | - Hanna K. Mandl
- Department of Surgery, UCLA, Los Angeles, California, USA
| | - Alex K. Lam
- Department of Molecular and Medical Pharmacology and
| | - Arthur Cho
- Department of Nuclear Medicine, Yonsei University College of Medicine, Seoul, South Korea
| | | | - Nanping Wu
- Department of Surgery, UCLA, Los Angeles, California, USA
| | | | | | - Steven D. Mittelman
- Division of Pediatric Endocrinology, UCLA Children’s Discovery and Innovation Institute, and
| | - Willy Hugo
- Division of Dermatology, Department of Medicine, UCLA, Los Angeles, California, USA
| | | | | | - Antoni Ribas
- Department of Molecular and Medical Pharmacology and
- Parker Institute for Cancer Immunotherapy, San Francisco, California, USA
- Division of Hematology/Oncology, Department of Medicine
- Division of Surgical Oncology, Department of Surgery
- Jonsson Comprehensive Cancer Center
| | - Timothy R. Donahue
- Department of Molecular and Medical Pharmacology and
- Department of Surgery, UCLA, Los Angeles, California, USA
- Jonsson Comprehensive Cancer Center
| | - Gay M. Crooks
- Division of Pediatric Hematology-Oncology, Department of Pediatrics
- Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, and
- Department of Pathology and Laboratory Medicine, UCLA, Los Angeles, California, USA
| | - Ting-Ting Wu
- Department of Molecular and Medical Pharmacology and
| | - Caius G. Radu
- Department of Molecular and Medical Pharmacology and
- Jonsson Comprehensive Cancer Center
| |
Collapse
|
2
|
Koul D, Balasubramaniyan V, Li X, Khan S, Guggi D, Mehrling T, DeGroot J. DDRE-33. PRECLINICAL THERAPEUTIC EFFICACY OF THE NOVEL BLOOD BRAIN BARRIER PENETRANT ATR INHIBITOR LR02 IN GLIOBLASTOMA. Neuro Oncol 2021. [DOI: 10.1093/neuonc/noab196.317] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Glioblastoma (GBM) remains an incurable tumor with median overall survival of 15 months despite radiation and alkylating temozolomide (TMZ) chemotherapy. DNA damage response (DDR) pathways are among the most important key players of oncogenic mutations associated with resistance to both chemotherapy and radiation in GBM. The high frequency of alterations in DDR pathways in GBM suggests that its inhibition by DDR inhibitors may render GBM cells more susceptible to DNA damaging interventions. Here, we report the preclinical in vitro and in vivo activity of a novel, orally bioavailable Ataxia-telangiectasia mutated serine/threonine protein kinase and Rad3-related (ATR) inhibitor LR02 (Laevoroc Oncology) in a panel of 15 well-characterized glioma stem-like cells (GSCs). Effects on cell proliferation, survival and tumor formation were analyzed following treatment with LR02. Growth inhibition was time- and dose-dependent with a 3-day exposure resulting in a growth inhibitory IC50 (gIC50) in the low nM range in all the glioblastoma cell lines tested. LR02 inhibited growth of GSCs at IC50 values ranging from 500nmol/L to-~2umol/L. Additional studies showed that temozolomide sensitized GSC to LR02. Importantly, we demonstrate that MGMT promotor methylation status was associated with cellular response to LR02 treatment with preferential inhibition of cell growth in MGMT promotor methylated (MGMT deficient) cell lines. LR02 showed efficacy and survival benefit in a GSC262 (MGMT methylated) orthotopic model of GBM. Further administration of LR02 further enhanced the in vivo antitumor efficacy of temozolomide (TMZ) against GBM using the GSC262 model demonstrating that ATR inhibitor LR02 may enhance alkylating agent-mediated cytotoxicity and provide a novel treatment combination for GBM patients. Our present findings establish that the ATR inhibitor LR02 can specifically be used in tumors with MGMT deficiency when combined with alkylating chemotherapy. Further studies are ongoing to evaluate the potential of LR02 to overcome radiation and chemotherapy resistance in glioblastoma.
Collapse
Affiliation(s)
- Dimpy Koul
- UT MD Anderson Cancer Center, Houston, TX, USA
| | | | - Xiaolong Li
- UT MD Anderson Cancer Center, Houston, TX, USA
| | - Sabbir Khan
- UT MD Anderson Cancer Center, Houston, TX, USA
| | | | | | | |
Collapse
|
3
|
Pape UF, Kasper S, Meiler J, Sinn M, Vogel A, Mueller L, Burkhard O, Caca K, Heeg S, Rodriguez Laval V, Kuhl A, Arsenic R, Jansen H, Mehrling T, Hilgier K, Wagner I, Utku N. Post-hoc analyses of a subgroup of patients with advanced biliary tract cancer (BTC) who crossed over to treatment with etoposide toniribate (EDO-S7.1) in a randomized phase II study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz247.051] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
4
|
Mita A, Loeffler M, Bui N, Remmy D, Mehrling T, Mita M, Rimel B, Natale R, Kummar S. A phase I study of tinostamustine in patients (pts) with advanced solid tumours. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz244.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
5
|
Mita A, Loeffler M, Bui N, Mehrling T, Rimmel BJ, Natale RB, Kummar S. Abstract CT023: Dose escalation of tinostamustine in patients with advanced solid tumors. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-ct023] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Despite advances in the treatment of solid tumors in recent years, unmet medical needs remain for patients with advanced disease. The alkylating deacetylase inhibiting molecule tinostamustine (EDO-S101) is a novel multi-action drug that has been shown in preclinical studies to improve drug access to the DNA strands within cancer cells, break them and counteract damage repair. Here we report findings from the dose escalation phase of an open-label Phase I/II study to investigate the safety, pharmacokinetics and efficacy of tinostamustine in patients with advanced solid tumors (NCT03345485).
In the Phase I part of the study, patients were recruited using a standard 3+3 design, with the first cohort receiving 60mg/m2 tinostamustine administered IV over 30 minutes, with six ascending cohorts to a maximum dose of 100mg/m2 administered over 30 or 60 minutes.
A total of 26 patients were screened and 22 patients enrolled into the study as the safety population. Patients had a mean ± SD age of 59.7 ± 11.1 years, 59.1% were female, 77.3% Caucasian and 22.7% Asian; all patients had received prior systemic therapy with or without radiotherapy. The (mean ± SD) tinostamustine dose was 407.3 ± 218.44 mg/m2, and the mean ± SD time on therapy was 10.4 ± 8.6 weeks. All patients experienced ≥1 treatment-emergent adverse events (TEAE), of which 22.7% were serious; 3 patients withdrew from the study due to TEAEs (CTCAE Grade 4 thrombocytopenia). The most common TEAEs related to study treatment were mild or moderate in intensity and included nausea (81.8% of patients), QTc prolongation (59.1%), thrombocytopenia (54.5%), anemia (45.5%), lymphopenia (40.9%), fatigue (36.4%), vomiting (31.8%) and leukopenia (31.8%). Importantly, despite a high percentage of patients experiencing some degree of QTc prolongation, external review determined that the majority of abnormalities were not clinically significant. Only one of the 22 patients enrolled (4.5%) experienced a QTc prolongation event that was considered to be clinically significant, this was a dose-limiting toxicity of Grade 3 QTc-prolongation in a patient receiving 100mg/m2 tinostamustine over 60 minutes. Nausea and vomiting were well managed using antiemetics. At 16 weeks’ follow-up, 4.5% of patients had a tumour response of partial response and 36.4% stable disease. Pharmacokinetic (PK) studies showed that peak serum concentrations (Cmax) of tinostamustine reached therapeutic levels. A more detailed analysis of PK data will be presented at the conference.
In patients with advanced solid tumors and limited treatment options, tinostamustine was generally well tolerated with preliminary signs of efficacy observed in this Phase I study across diverse tumor types. The Phase II portion of this study will enable a more comprehensive assessment of the efficacy of tinostamustine in larger patient cohorts within five specific tumor types.
Funding: Mundipharma-EDO GmbH.
Citation Format: Alain Mita, Markus Loeffler, Nam Bui, Thomas Mehrling, Bobbie J. Rimmel, Ronald B. Natale, Shivaani Kummar. Dose escalation of tinostamustine in patients with advanced solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr CT023.
Collapse
Affiliation(s)
- Alain Mita
- 1Cedars-Sinai Medical Center, Los Angeles, CA
| | | | - Nam Bui
- 3Stanford Cancer Institute, Stanford University, Stanford, CA
| | | | | | | | - Shivaani Kummar
- 3Stanford Cancer Institute, Stanford University, Stanford, CA
| |
Collapse
|
6
|
Pinto A, De Filippi R, Zinzani P, Driessen C, Tun H, Hilgier K, Remmy D, Mehrling T, O'Connor O. A FIRST-IN-HUMAN TRIAL OF THE NOVEL MULTI-ACTION THERAPY TINOSTAMUSTINE (EDO-S101) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) HODGKIN LYMPHOMA (HL). Hematol Oncol 2019. [DOI: 10.1002/hon.137_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- A. Pinto
- Department of Hematology; University Federico II; Naples Italy
| | - R. De Filippi
- Department of Clinical Medicine and Surgery; University Federico II; Naples Italy
| | - P. Zinzani
- Department of Experimental; Diagnostic and Specialty Medicine, University of Bologna; Bologna Italy
| | - C. Driessen
- Interdisziplinäre Medizinische Dienste; Kantonsspital St Gallen; St Gallen Switzerland
| | - H.W. Tun
- Department of Hematology/Oncology; Mayo Clinic Cancer Center; Jacksonville United States
| | - K. Hilgier
- Clinical Development; Mundipharma EDO; Basel Switzerland
| | - D. Remmy
- Clinical Development; Mundipharma EDO; Basel Switzerland
| | - T. Mehrling
- Clinical Development; Mundipharma EDO; Basel Switzerland
| | - O.A. O'Connor
- Department of Medicine; Colombia University Medical Center; New York United States
| |
Collapse
|
7
|
O'Connor OA, Marchi E, Volinn W, Shi J, Mehrling T, Kim WS. Strategy for Assessing New Drug Value in Orphan Diseases: An International Case Match Control Analysis of the PROPEL Study. JNCI Cancer Spectr 2018; 2:pky038. [PMID: 31360868 PMCID: PMC6649793 DOI: 10.1093/jncics/pky038] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2018] [Revised: 06/14/2018] [Accepted: 07/11/2018] [Indexed: 11/17/2022] Open
Abstract
Background Although randomized studies are designed to assess overall survival (OS) benefit, the conduct of regulatory studies in patients with orphan diseases can be timely and costly without offering the same commercial return on the investment. The peripheral T-cell lymphomas (PTCL) represent a rare group of heterogeneous lymphoid malignancies with very poor prognosis. PROPEL was a pivotal phase II study that led to the accelerated approval of pralatrexate for patients with relapsed or refractory PTCL. Methods An international database of 859 patients was assembled from four institutions with an interest in PTCL, of which 386 were considered eligible for matching against the PROPEL criteria. Using a rigorous propensity score matching algorithm, a unique 1:1 case match of 80 patients was performed. Results The analysis demonstrated an OS benefit for the PROPEL population with a median OS of 4.07 and 15.24 months (hazard ratio = 0.432, 95% confidence interval = 0.298 to 0.626), respectively, for the control and PROPEL populations. Highly statistically significant improvements in OS were noted for the PROPEL population about the subtype of PTCL (save anaplastic large cell lymphoma) and all age groups, including the elderly (>65 years of age). For patients on PROPEL, there was a statistically significant prolongation in progression free survival compared with the line of prior therapy, including those with refractory disease. Conclusion In the context of this case-match-control study, patients treated on PROPEL experienced an OS advantage compared with an international database of historical controls. This information can help inform critical decision-making regarding clinical studies in PTCL.
Collapse
Affiliation(s)
- Owen A O'Connor
- Department of Medicine, Center for Lymphoid Malignancies, Columbia University Medical Center, College of Physicians and Surgeons, New York, NY
| | - Enrica Marchi
- Department of Medicine, Center for Lymphoid Malignancies, Columbia University Medical Center, College of Physicians and Surgeons, New York, NY
| | | | | | | | | |
Collapse
|
8
|
M'kacher R, Frenzel M, Al Jawhari M, Junker S, Cuceu C, Morat L, Bauchet AL, Stimmer L, Lenain A, Dechamps N, Hempel WM, Pottier G, Heidingsfelder L, Laplagne E, Borie C, Oudrhiri N, Jouni D, Bennaceur-Griscelli A, Colicchio B, Dieterlen A, Girinsky T, Boisgard R, Bourhis J, Bosq J, Mehrling T, Jeandidier E, Carde P. Establishment and Characterization of a Reliable Xenograft Model of Hodgkin Lymphoma Suitable for the Study of Tumor Origin and the Design of New Therapies. Cancers (Basel) 2018; 10:cancers10110414. [PMID: 30384446 PMCID: PMC6265845 DOI: 10.3390/cancers10110414] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2018] [Revised: 10/25/2018] [Accepted: 10/26/2018] [Indexed: 01/16/2023] Open
Abstract
To identify the cells responsible for the initiation and maintenance of Hodgkin lymphoma (HL) cells, we have characterized a subpopulation of HL cells grown in vitro and in vivo with the aim of establishing a reliable and robust animal model for HL. To validate our model, we challenged the tumor cells in vivo by injecting the alkylating histone-deacetylase inhibitor, EDO-S101, a salvage regimen for HL patients, into xenografted mice. Methodology: Blood lymphocytes from 50 HL patients and seven HL cell lines were used. Immunohistochemistry, flow cytometry, and cytogenetics analyses were performed. The in vitro and in vivo effects of EDO-S101 were assessed. Results: We have successfully determined conditions for in vitro amplification and characterization of the HL L428-c subline, containing a higher proportion of CD30−/CD15− cells than the parental L428 cell line. This subline displayed excellent clonogenic potential and reliable reproducibility upon xenografting into immunodeficient NOD-SCID-gamma (−/−)(NSG) mice. Using cell sorting, we demonstrate that CD30−/CD15− subpopulations can gain the phenotype of the L428-c cell line in vitro. Moreover, the human cells recovered from the seventh week after injection of L428-c cells into NSG mice were small cells characterized by a high frequency of CD30−/CD15− cells. Cytogenetic analysis demonstrated that they were diploid and showed high telomere instability and telomerase activity. Accordingly, chromosomal instability emerged, as shown by the formation of dicentric chromosomes, ring chromosomes, and breakage/fusion/bridge cycles. Similarly, high telomerase activity and telomere instability were detected in circulating lymphocytes from HL patients. The beneficial effect of the histone-deacetylase inhibitor EDO-S101 as an anti-tumor drug validated our animal model. Conclusion: Our HL animal model requires only 103 cells and is characterized by a high survival/toxicity ratio and high reproducibility. Moreover, the cells that engraft in mice are characterized by a high frequency of small CD30−/CD15− cells exhibiting high telomerase activity and telomere dysfunction.
Collapse
Affiliation(s)
- Radhia M'kacher
- Radiobiology and Oncology Laboratory, CEA, iRCM, University Paris-Saclay, 92 265 Fontenay aux Roses, France.
- Cell Environment, Oncology Section, 75020 Paris, France.
| | - Monika Frenzel
- Radiobiology and Oncology Laboratory, CEA, iRCM, University Paris-Saclay, 92 265 Fontenay aux Roses, France.
| | - Mustafa Al Jawhari
- Radiobiology and Oncology Laboratory, CEA, iRCM, University Paris-Saclay, 92 265 Fontenay aux Roses, France.
| | - Steffen Junker
- Institute of Biomedicine, University of Aarhus, DK-8000 Aarhus C, Denmark.
| | - Corina Cuceu
- Radiobiology and Oncology Laboratory, CEA, iRCM, University Paris-Saclay, 92 265 Fontenay aux Roses, France.
| | - Luc Morat
- Radiobiology and Oncology Laboratory, CEA, iRCM, University Paris-Saclay, 92 265 Fontenay aux Roses, France.
| | - Anne-Laure Bauchet
- Platform for Experimental Pathology PathEX/CRC MIRCen/CEA-INSERM, University Paris-Saclay, 92265 Fontenay aux Rroses, France.
| | - Lev Stimmer
- Platform for Experimental Pathology PathEX/CRC MIRCen/CEA-INSERM, University Paris-Saclay, 92265 Fontenay aux Rroses, France.
| | - Aude Lenain
- Radiobiology and Oncology Laboratory, CEA, iRCM, University Paris-Saclay, 92 265 Fontenay aux Roses, France.
| | - Nathalie Dechamps
- Platform for Cell Sorting, CEA, iRCM, 92265 Fontenay aux Roses, France.
| | - William M Hempel
- Radiobiology and Oncology Laboratory, CEA, iRCM, University Paris-Saclay, 92 265 Fontenay aux Roses, France.
| | - Geraldine Pottier
- Laboratoire d'Imagerie Moléculaire Expérimentale Groupe d'Imagerie du Petit Animal CEA/DSV/I2BM/SHFJ/U1023, University Paris-Saclay, 91400 Orsay, France.
| | | | | | - Claire Borie
- APHP-Hopital Paul Brousse Université Paris Sud/ESteam Paris Inserm UMR 935, 94800 Villejuif, France.
| | - Noufissa Oudrhiri
- APHP-Hopital Paul Brousse Université Paris Sud/ESteam Paris Inserm UMR 935, 94800 Villejuif, France.
| | - Dima Jouni
- APHP-Hopital Paul Brousse Université Paris Sud/ESteam Paris Inserm UMR 935, 94800 Villejuif, France.
| | | | - Bruno Colicchio
- IRIMAS, Institut de Recherche en Informatique, Mathématiques, Automatique et Signal, Université de Haute-Alsace, 68093 Mulhouse, France.
| | - Alain Dieterlen
- IRIMAS, Institut de Recherche en Informatique, Mathématiques, Automatique et Signal, Université de Haute-Alsace, 68093 Mulhouse, France.
| | - Theodore Girinsky
- Department of Radiation Oncology, Gustave Roussy Cancer Campus, University Paris-Saclay, 94805 Villejuif, France.
| | - Raphael Boisgard
- Laboratoire d'Imagerie Moléculaire Expérimentale Groupe d'Imagerie du Petit Animal CEA/DSV/I2BM/SHFJ/U1023, University Paris-Saclay, 91400 Orsay, France.
| | - Jean Bourhis
- Department of Radiation Oncology, Gustave Roussy Cancer Campus, University Paris-Saclay, 94805 Villejuif, France.
| | - Jacques Bosq
- Departement of Anapathology, Gustave Roussy Cancer Campus, University Paris-Saclay, 94805 Vilejuif, France.
| | | | - Eric Jeandidier
- Department of Genetic, Groupe Hospitalier de la Région de Mulhouse Sud-Alsace, 68093 Mulhouse, France.
| | - Patrice Carde
- Department of Medicine, Gustave Roussy Cancer Campus, University Paris-Saclay, 94805 Villejuif, France.
| |
Collapse
|
9
|
Mehrling T, Soltis D. Correction: Mehrling, T.; et al. Challenges in Optimising the Successful Construction of Antibody Drug Conjugates in Cancer Therapy. Antibodies 2018, 7, 11. Antibodies (Basel) 2018; 7:E32. [PMID: 31544883 PMCID: PMC6640681 DOI: 10.3390/antib7030032] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2018] [Accepted: 08/22/2018] [Indexed: 11/16/2022] Open
Abstract
The Conflict of Interest section of the published paper [1] has been updated as follows: [...].
Collapse
|
10
|
Qiu Y, Li Z, Copland JA, Mehrling T, Tun HW. Combined alkylation and histone deacetylase inhibition with EDO-S101 has significant therapeutic activity against brain tumors in preclinical models. Oncotarget 2018; 9:28155-28164. [PMID: 29963268 PMCID: PMC6021334 DOI: 10.18632/oncotarget.25588] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2017] [Accepted: 05/24/2018] [Indexed: 12/22/2022] Open
Abstract
There is a clear unmet need for novel therapeutic agents for management of primary and secondary brain tumors. Novel therapeutic agents with excellent central nervous system (CNS) penetration and therapeutic activity are urgently needed. EDO-S101 is a novel alkylating and histone deacetylase inhibiting agent created by covalent fusion of bendamustine and vorinostat. We used murine models to perform CNS pharmacokinetic analysis and preclinical therapeutic evaluation of EDO-S101 for CNS lymphoma, metastatic triple-negative breast cancer of the brain, and glioblastoma multiforme. EDO-S101 has excellent CNS penetration of 13.8% and 16.5% by intravenous infusion and bolus administration respectively. It shows promising therapeutic activity against CNS lymphoma, metastatic triple-negative breast cancer of the brain, and glioblastoma multiforme with significant prolongation of survival compared to no-treatment controls. Therapeutic activity was higher with IV infusion compared to IV bolus. It should be evaluated further for therapeutic use in brain tumors.
Collapse
Affiliation(s)
- Yushi Qiu
- Department of Cancer Biology, Mayo Clinic, Jacksonville, FL 32224, USA
| | - Zhimin Li
- Department of Cancer Biology, Mayo Clinic, Jacksonville, FL 32224, USA
| | - John A Copland
- Department of Cancer Biology, Mayo Clinic, Jacksonville, FL 32224, USA
| | | | - Han W Tun
- Department of Cancer Biology, Mayo Clinic, Jacksonville, FL 32224, USA.,Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL 32224, USA
| |
Collapse
|
11
|
Gross M, Engel J, Good J, Huck H, Isaev I, Koss G, Krasilnikov M, Lishilin O, Loisch G, Renier Y, Rublack T, Stephan F, Brinkmann R, Martinez de la Ossa A, Osterhoff J, Malyutin D, Richter D, Mehrling T, Khojoyan M, Schroeder CB, Grüner F. Observation of the Self-Modulation Instability via Time-Resolved Measurements. Phys Rev Lett 2018; 120:144802. [PMID: 29694120 DOI: 10.1103/physrevlett.120.144802] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/30/2017] [Indexed: 06/08/2023]
Abstract
Self-modulation of an electron beam in a plasma has been observed. The propagation of a long (several plasma wavelengths) electron bunch in an overdense plasma resulted in the production of multiple bunches via the self-modulation instability. Using a combination of a radio-frequency deflector and a dipole spectrometer, the time and energy structure of the self-modulated beam was measured. The longitudinal phase space measurement showed the modulation of a long electron bunch into three bunches with an approximately 200 keV/c amplitude momentum modulation. Demonstrating this effect is a breakthrough for proton-driven plasma accelerator schemes aiming to utilize the same physical effect.
Collapse
Affiliation(s)
- M Gross
- Deutsches Elektronen-Synchrotron DESY, Platanenallee 6, 15738 Zeuthen, Germany
| | - J Engel
- Deutsches Elektronen-Synchrotron DESY, Platanenallee 6, 15738 Zeuthen, Germany
| | - J Good
- Deutsches Elektronen-Synchrotron DESY, Platanenallee 6, 15738 Zeuthen, Germany
| | - H Huck
- Deutsches Elektronen-Synchrotron DESY, Platanenallee 6, 15738 Zeuthen, Germany
| | - I Isaev
- Deutsches Elektronen-Synchrotron DESY, Platanenallee 6, 15738 Zeuthen, Germany
| | - G Koss
- Deutsches Elektronen-Synchrotron DESY, Platanenallee 6, 15738 Zeuthen, Germany
| | - M Krasilnikov
- Deutsches Elektronen-Synchrotron DESY, Platanenallee 6, 15738 Zeuthen, Germany
| | - O Lishilin
- Deutsches Elektronen-Synchrotron DESY, Platanenallee 6, 15738 Zeuthen, Germany
| | - G Loisch
- Deutsches Elektronen-Synchrotron DESY, Platanenallee 6, 15738 Zeuthen, Germany
| | - Y Renier
- Deutsches Elektronen-Synchrotron DESY, Platanenallee 6, 15738 Zeuthen, Germany
| | - T Rublack
- Deutsches Elektronen-Synchrotron DESY, Platanenallee 6, 15738 Zeuthen, Germany
| | - F Stephan
- Deutsches Elektronen-Synchrotron DESY, Platanenallee 6, 15738 Zeuthen, Germany
| | - R Brinkmann
- Deutsches Elektronen-Synchrotron DESY, Notkestr. 85, 22607 Hamburg, Germany
| | - A Martinez de la Ossa
- Deutsches Elektronen-Synchrotron DESY, Notkestr. 85, 22607 Hamburg, Germany
- Universität Hamburg, Luruper Chaussee 149, 22761 Hamburg, Germany
| | - J Osterhoff
- Deutsches Elektronen-Synchrotron DESY, Notkestr. 85, 22607 Hamburg, Germany
| | - D Malyutin
- Helmholtz-Zentrum Berlin für Materialien & Energie, Albert-Einstein-Strasse 15, 12489 Berlin, Germany
| | - D Richter
- Helmholtz-Zentrum Berlin für Materialien & Energie, Albert-Einstein-Strasse 15, 12489 Berlin, Germany
| | - T Mehrling
- Universität Hamburg, Luruper Chaussee 149, 22761 Hamburg, Germany
- Instituto Superior Técnico, Avenida Rovisco Pais 1, 1049-001 Lisbon, Portugal
| | - M Khojoyan
- LLR (Laboratoire Leprince-Ringuet), CNRS and Ecole Polytechnique, Palaiseau UMR7638, France
| | - C B Schroeder
- Lawrence Berkeley National Laboratory, 1 Cyclotron Road, Berkeley, California 94720, USA
| | - F Grüner
- Universität Hamburg, Luruper Chaussee 149, 22761 Hamburg, Germany
- Center for Free-Electron Laser Science, Notkestrasse 85, 22607 Hamburg, Germany
| |
Collapse
|
12
|
Festuccia C, Mancini A, Colapietro A, Gravina GL, Vitale F, Marampon F, Delle Monache S, Pompili S, Cristiano L, Vetuschi A, Tombolini V, Chen Y, Mehrling T. Correction to: The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma. J Hematol Oncol 2018. [PMID: 29540202 PMCID: PMC5853051 DOI: 10.1186/s13045-018-0587-3] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Affiliation(s)
- C Festuccia
- Laboratory of Radiobiology, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy.
| | - A Mancini
- Laboratory of Radiobiology, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy
| | - A Colapietro
- Laboratory of Radiobiology, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy
| | - G L Gravina
- Laboratory of Radiobiology, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy.,Division of Radiotherapy, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy
| | - F Vitale
- Division of Neurosciences, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy
| | - F Marampon
- Division of Radiotherapy, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy
| | - S Delle Monache
- Division of Applied Biology, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy
| | - S Pompili
- Division of Human Anatomy, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy
| | - L Cristiano
- Laboratory of Applied Biology, Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy
| | - A Vetuschi
- Division of Human Anatomy, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy
| | - V Tombolini
- Division of Radiotherapy, Department of Experimental Medicine, University of Rome "La Sapienza", Rome, Italy
| | - Y Chen
- Northlake International LLC, Pleasanton, CA, USA
| | - T Mehrling
- Mundipharma-EDO GmbH, Basel, Switzerland
| |
Collapse
|
13
|
Festuccia C, Mancini A, Colapietro A, Gravina GL, Vitale F, Marampon F, Delle Monache S, Pompili S, Cristiano L, Vetuschi A, Tombolini V, Chen Y, Mehrling T. The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma. J Hematol Oncol 2018; 11:32. [PMID: 29486795 PMCID: PMC5830080 DOI: 10.1186/s13045-018-0576-6] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2017] [Accepted: 02/14/2018] [Indexed: 12/14/2022] Open
Abstract
Background The use of alkylating agents such as temozolomide in association with radiotherapy (RT) is the therapeutic standard of glioblastoma (GBM). This regimen modestly prolongs overall survival, also if, in light of the still dismal prognosis, further improvements are desperately needed, especially in the patients with O6-methylguanine-DNA-methyltransferase (MGMT) unmethylated tumors, in which the benefit of standard treatment is less. Tinostamustine (EDO-S101) is a first-in-class alkylating deacetylase inhibitor (AK-DACi) molecule that fuses the DNA damaging effect of bendamustine with the fully functional pan-histone deacetylase (HDAC) inhibitor, vorinostat, in a completely new chemical entity. Methods Tinostamustine has been tested in models of GBM by using 13 GBM cell lines and seven patient-derived GBM proliferating/stem cell lines in vitro. U87MG and U251MG (MGMT negative), as well as T98G (MGMT positive), were subcutaneously injected in nude mice, whereas luciferase positive U251MG cells and patient-derived GBM stem cell line (CSCs-5) were evaluated the orthotopic intra-brain in vivo experiments. Results We demonstrated that tinostamustine possesses stronger antiproliferative and pro-apoptotic effects than those observed for vorinostat and bendamustine alone and similar to their combination and irrespective of MGMT expression. In addition, we observed a stronger radio-sensitization of single treatment and temozolomide used as control due to reduced expression and increased time of disappearance of γH2AX indicative of reduced signal and DNA repair. This was associated with higher caspase-3 activation and reduction of RT-mediated autophagy. In vivo, tinostamustine increased time-to-progression (TTP) and this was additive/synergistic to RT. Tinostamustine had significant therapeutic activity with suppression of tumor growth and prolongation of DFS (disease-free survival) and OS (overall survival) in orthotopic intra-brain models that was superior to bendamustine, RT and temozolomide and showing stronger radio sensitivity. Conclusions Our data suggest that tinostamustine deserves further investigation in patients with glioblastoma. Electronic supplementary material The online version of this article (10.1186/s13045-018-0576-6) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Claudio Festuccia
- Laboratory of Radiobiology, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy.
| | - Andrea Mancini
- Laboratory of Radiobiology, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy
| | - Alessandro Colapietro
- Laboratory of Radiobiology, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy
| | - Giovanni Luca Gravina
- Laboratory of Radiobiology, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy.,Division of Radiotherapy, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy
| | - Flora Vitale
- Division of Neurosciences, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy
| | - Francesco Marampon
- Division of Radiotherapy, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy
| | - Simona Delle Monache
- Division of Applied Biology, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy
| | - Simona Pompili
- Division of Human Anatomy, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy
| | - Loredana Cristiano
- Laboratory of Applied Biology, Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy
| | - Antonella Vetuschi
- Division of Human Anatomy, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy
| | - Vincenzo Tombolini
- Division of Radiotherapy, Department of Experimental Medicine, University of Rome "La Sapienza", Rome, Italy
| | - Yi Chen
- Northlake International LLC, Pleasanton, CA, USA
| | | |
Collapse
|
14
|
Besse L, Kraus M, Besse A, Bader J, Silzle T, Mehrling T, Driessen C. The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways. Blood Cancer J 2017; 7:e589. [PMID: 28753594 PMCID: PMC5549260 DOI: 10.1038/bcj.2017.69] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Affiliation(s)
- L Besse
- Department of Oncology and Hematology, Cantonal Hospital St Gallen, St Gallen, Switzerland
| | - M Kraus
- Department of Oncology and Hematology, Cantonal Hospital St Gallen, St Gallen, Switzerland
| | - A Besse
- Department of Oncology and Hematology, Cantonal Hospital St Gallen, St Gallen, Switzerland
| | - J Bader
- Department of Oncology and Hematology, Cantonal Hospital St Gallen, St Gallen, Switzerland
| | - T Silzle
- Department of Oncology and Hematology, Cantonal Hospital St Gallen, St Gallen, Switzerland
| | - T Mehrling
- Mundipharma-EDO GmbH, Basel, Switzerland
| | - C Driessen
- Department of Oncology and Hematology, Cantonal Hospital St Gallen, St Gallen, Switzerland
| |
Collapse
|
15
|
López-Iglesias AA, Herrero AB, Chesi M, San-Segundo L, González-Méndez L, Hernández-García S, Misiewicz-Krzeminska I, Quwaider D, Martín-Sánchez M, Primo D, Paíno T, Bergsagel PL, Mehrling T, González-Díaz M, San-Miguel JF, Mateos MV, Gutiérrez NC, Garayoa M, Ocio EM. Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair. J Hematol Oncol 2017. [PMID: 28633670 PMCID: PMC5477689 DOI: 10.1186/s13045-017-0495-y] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Background Despite recent advances in the treatment of multiple myeloma (MM), the prognosis of most patients remains poor, and resistance to traditional and new drugs frequently occurs. EDO-S101 is a novel therapeutic agent conceived as the fusion of a histone deacetylase inhibitor radical to bendamustine, with the aim of potentiating its alkylating activity. Methods The efficacy of EDO-S101 was evaluated in vitro, ex vivo and in vivo, alone, and in combination with standard anti-myeloma agents. The underlying mechanisms of action were also evaluated on MM cell lines, patient samples, and different murine models. Results EDO-S101 displayed potent activity in vitro in MM cell lines (IC50 1.6–4.8 μM) and ex vivo in cells isolated from MM patients, which was higher than that of bendamustine and independent of the p53 status and previous melphalan resistance. This activity was confirmed in vivo, in a CB17-SCID murine plasmacytoma model and in de novo Vk*MYC mice, leading to a significant survival improvement in both models. In addition, EDO-S101 was the only drug with single-agent activity in the multidrug resistant Vk12653 murine model. Attending to its mechanism of action, the molecule showed both, a HDACi effect (demonstrated by α-tubulin and histone hyperacetylation) and a DNA-damaging effect (shown by an increase in γH2AX); the latter being again clearly more potent than that of bendamustine. Using a reporter plasmid integrated into the genome of some MM cell lines, we demonstrate that, apart from inducing a potent DNA damage, EDO-S101 specifically inhibited the double strand break repair by the homologous recombination pathway. Moreover, EDO-S101 treatment reduced the recruitment of repair proteins such as RAD51 to DNA-damage sites identified as γH2AX foci. Finally, EDO-S101 preclinically synergized with bortezomib, both in vitro and in vivo. Conclusion These findings provide rationale for the clinical investigation of EDO-S101 in MM, either as a single agent or in combination with other anti-MM drugs, particularly proteasome inhibitors. Electronic supplementary material The online version of this article (doi:10.1186/s13045-017-0495-y) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Ana-Alicia López-Iglesias
- University Hospital of Salamanca (IBSAL) & Cancer Research Center (IBMCC-CSIC-USAL), Salamanca, Spain
| | - Ana B Herrero
- University Hospital of Salamanca (IBSAL) & Cancer Research Center (IBMCC-CSIC-USAL), Salamanca, Spain
| | - Marta Chesi
- Comprehensive Cancer Center, Mayo Clinic, Arizona, USA
| | - Laura San-Segundo
- University Hospital of Salamanca (IBSAL) & Cancer Research Center (IBMCC-CSIC-USAL), Salamanca, Spain
| | - Lorena González-Méndez
- University Hospital of Salamanca (IBSAL) & Cancer Research Center (IBMCC-CSIC-USAL), Salamanca, Spain
| | - Susana Hernández-García
- University Hospital of Salamanca (IBSAL) & Cancer Research Center (IBMCC-CSIC-USAL), Salamanca, Spain
| | | | - Dalia Quwaider
- University Hospital of Salamanca (IBSAL) & Cancer Research Center (IBMCC-CSIC-USAL), Salamanca, Spain
| | - Montserrat Martín-Sánchez
- University Hospital of Salamanca (IBSAL) & Cancer Research Center (IBMCC-CSIC-USAL), Salamanca, Spain
| | | | - Teresa Paíno
- University Hospital of Salamanca (IBSAL) & Cancer Research Center (IBMCC-CSIC-USAL), Salamanca, Spain.
| | | | | | - Marcos González-Díaz
- University Hospital of Salamanca (IBSAL) & Cancer Research Center (IBMCC-CSIC-USAL), Salamanca, Spain
| | - Jesús F San-Miguel
- Center for Applied Medical Research (CIMA), IDISNA, University Clinic of Navarra, Pamplona, Spain
| | - María-Victoria Mateos
- University Hospital of Salamanca (IBSAL) & Cancer Research Center (IBMCC-CSIC-USAL), Salamanca, Spain
| | - Norma C Gutiérrez
- University Hospital of Salamanca (IBSAL) & Cancer Research Center (IBMCC-CSIC-USAL), Salamanca, Spain
| | - Mercedes Garayoa
- University Hospital of Salamanca (IBSAL) & Cancer Research Center (IBMCC-CSIC-USAL), Salamanca, Spain
| | - Enrique M Ocio
- University Hospital of Salamanca (IBSAL) & Cancer Research Center (IBMCC-CSIC-USAL), Salamanca, Spain
| |
Collapse
|
16
|
Brinkmann R, Delbos N, Dornmair I, Kirchen M, Assmann R, Behrens C, Floettmann K, Grebenyuk J, Gross M, Jalas S, Mehrling T, Martinez de la Ossa A, Osterhoff J, Schmidt B, Wacker V, Maier AR. Chirp Mitigation of Plasma-Accelerated Beams by a Modulated Plasma Density. Phys Rev Lett 2017; 118:214801. [PMID: 28598675 DOI: 10.1103/physrevlett.118.214801] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/08/2015] [Indexed: 06/07/2023]
Abstract
Plasma-based accelerators offer the possibility to drive future compact light sources and high-energy physics applications. Achieving good beam quality, especially a small beam energy spread, is still one of the major challenges. Here, we propose to use a periodically modulated plasma density to shape the longitudinal fields acting on an electron bunch in the linear wakefield regime. With simulations, we demonstrate an on-average flat accelerating field that maintains a small beam energy spread.
Collapse
Affiliation(s)
- R Brinkmann
- Deutsches Elektronen-Synchrotron DESY, Notkestrasse 85, 22607 Hamburg, Germany
| | - N Delbos
- Center for Free-Electron Laser Science and Department of Physics, University of Hamburg, Luruper Chaussee 149, 22761 Hamburg, Germany
| | - I Dornmair
- Center for Free-Electron Laser Science and Department of Physics, University of Hamburg, Luruper Chaussee 149, 22761 Hamburg, Germany
| | - M Kirchen
- Center for Free-Electron Laser Science and Department of Physics, University of Hamburg, Luruper Chaussee 149, 22761 Hamburg, Germany
| | - R Assmann
- Deutsches Elektronen-Synchrotron DESY, Notkestrasse 85, 22607 Hamburg, Germany
| | - C Behrens
- Deutsches Elektronen-Synchrotron DESY, Notkestrasse 85, 22607 Hamburg, Germany
| | - K Floettmann
- Deutsches Elektronen-Synchrotron DESY, Notkestrasse 85, 22607 Hamburg, Germany
| | - J Grebenyuk
- Deutsches Elektronen-Synchrotron DESY, Notkestrasse 85, 22607 Hamburg, Germany
| | - M Gross
- Deutsches Elektronen-Synchrotron DESY, Platanenallee 6, 15738 Zeuthen, Germany
| | - S Jalas
- Center for Free-Electron Laser Science and Department of Physics, University of Hamburg, Luruper Chaussee 149, 22761 Hamburg, Germany
| | - T Mehrling
- Deutsches Elektronen-Synchrotron DESY, Notkestrasse 85, 22607 Hamburg, Germany
| | | | - J Osterhoff
- Deutsches Elektronen-Synchrotron DESY, Notkestrasse 85, 22607 Hamburg, Germany
| | - B Schmidt
- Deutsches Elektronen-Synchrotron DESY, Notkestrasse 85, 22607 Hamburg, Germany
| | - V Wacker
- Deutsches Elektronen-Synchrotron DESY, Notkestrasse 85, 22607 Hamburg, Germany
| | - A R Maier
- Center for Free-Electron Laser Science and Department of Physics, University of Hamburg, Luruper Chaussee 149, 22761 Hamburg, Germany
| |
Collapse
|
17
|
Mehrling T, Chen Y. The Alkylating-HDAC Inhibition Fusion Principle: Taking Chemotherapy to the Next Level with the First in Class Molecule EDO-S101. Anticancer Agents Med Chem 2016; 16:20-8. [PMID: 25980817 DOI: 10.2174/1871520615666150518092027] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2015] [Revised: 03/02/2015] [Accepted: 05/15/2015] [Indexed: 11/22/2022]
Abstract
Chemotherapy may still be an essential component to treat cancer in combination with new targeted therapies. But chemotherapy needs to get smarter in order to make those combination regimens more effective and also more tolerable, particularly for an aging population. We describe the first time the synthesis and pharmacological testing of a fusion molecule comprising of the alkylator bendamustine and the HDAC-inhibitor vorinostat. The drug was designed to allow for the exploitation of both mechanisms of action simultaneously with the goal to provide a molecule with superior efficacy over the single agents. The pharmacological testing confirms the full functional capacity of both moieties and encouraging pharmacological data raises the hope that the drug may turn out to be a great addition to the armentarium of anticancer agents.
Collapse
Affiliation(s)
- Thomas Mehrling
- Thomas Mehrling, Mundipharma-EDO GmbH, St. Alban Rheinweg 74, 4052 Basel, Switzerland.
| | | |
Collapse
|
18
|
Mehrling T. Is there hope to treat glioblastoma effectively? CNS Oncol 2015; 4:377-9. [DOI: 10.2217/cns.15.33] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Thomas Mehrling speaks to Roshaine Gunawardana, Commissioning Editor: Thomas Mehrling was appointed Managing Director of Mundipharma EDO GmbH, Basel, in January 2013 and brings extensive experience with more than 17 years in the industry to this role. During his career, he has held various senior positions in different companies across almost all functions in drug development and commercialization. Most recently, he held the position of International Director Oncology Strategy (2011–2013). From 2004 to 2011 he served as European Director Oncology at Mundipharma International Ltd. During his tenure the oncology business of the European Mundipharma network of independent associated companies was set up and two major products were launched in Europe, DepoCyte® and Levact® (Ribomustin®, Treanda®). He joined Mundipharma in 2000 as Head of Business Development. Prior to Mundipharma, he was Senior Vice President of the global CRO Medical Affairs at Staticon International, and prior to this he acted as Medical Leader at Takeda European R&D center. Dr. Mehrling is a certified Pharmacist with a PhD in pharmacology and a certified Physician trained in haemato-oncology. He obtained his PhD from Frankfurt University following work on developing a new 5-HT3 antagonist to treat nausea and vomiting and developed a particular interest in mechanisms of multidrug resistance into chemotherapy. Dr. Mehrling earned his MD degree through his work in the Department of Internal medicine at Frankfurt University (Hemato-oncology and Cardiology) where he worked for several years before starting his career in the pharmaceutical industry.
Collapse
Affiliation(s)
- Thomas Mehrling
- Mundipharma EDO GmbH, St. Alban-Rheinweg 74, CH-4020, Basel, Switzerland
| |
Collapse
|
19
|
|
20
|
Mehrling T, Ricevuto E, Gravina GL, Mancini A, Festuccia C. Activity of the alkylating histone-deacetylase inhibition fusion molecule EDO-S-101 in preclinical models of human glioblastoma independent from MGMT expression. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.e13031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Enrico Ricevuto
- Medical Oncology, S. Salvatore Hospital, Department of Biotechnological and Applied Clinical Sciences, University of LAquila, L'Aquila, Italy
| | | | | | | |
Collapse
|
21
|
Wilson WH, Bromberg JEC, Stetler-Stevenson M, Steinberg SM, Martin-Martin L, Muñiz C, Sancho JM, Caballero MD, Davidis MA, Brooimans RA, Sanchez-Gonzalez B, Salar A, González-Barca E, Ribera JM, Shovlin M, Filie A, Dunleavy K, Mehrling T, Spina M, Orfao A. Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma. Haematologica 2014; 99:1228-35. [PMID: 24727817 DOI: 10.3324/haematol.2013.101741] [Citation(s) in RCA: 58] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
The benefit of intrathecal therapy and systemic rituximab on the outcome of diffuse large B-cell lymphoma at risk of central nervous system disease is controversial. Furthermore, the effect of intrathecal treatment and rituximab in diffuse large B-cell and Burkitt lymphoma with occult leptomeningeal disease detected by flow cytometry at diagnosis is unknown. Untreated diffuse large B-cell (n=246) and Burkitt (n=80) lymphoma at clinical risk of central nervous system disease and having had pre-treatment cerebrospinal fluid were analyzed by flow cytometry and cytology. Spinal fluid involvement was detected by flow cytometry alone (occult) in 33 (13%) diffuse large B-cell and 9 (11%) Burkitt lymphoma patients, and detected by cytology in 11 (4.5%) and 5 (6%) patients, respectively. Diffuse large B-cell lymphoma with occult spinal fluid involvement had poorer survival (P=0.0001) and freedom from central nervous system relapse (P<0.0001) compared to negative cases. Burkitt lymphoma with occult spinal fluid involvement had an inferior freedom from central nervous system relapse (P=0.026) but not survival. The amount of intrathecal chemotherapy was quantitatively associated with survival in diffuse large B-cell lymphoma with (P=0.02) and without (P=0.001) occult spinal fluid involvement. However, progression of systemic disease and not control of central nervous system disease was the principal cause of treatment failure. In diffuse large B-cell lymphoma, systemic rituximab was associated with improved freedom from central nervous system relapse (P=0.003) but not with survival. Our results suggest that patients at risk of central nervous system disease should be evaluated by flow cytometry and that intrathecal prophylaxis/therapy is beneficial.
Collapse
Affiliation(s)
- Wyndham H Wilson
- Lymphoid Malignancy Branch, National Cancer Institute, Bethesda, MD, USA
| | - Jacoline E C Bromberg
- Department of Neuro-Oncology, Daniel den Hoed Cancer Center, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
| | | | - Seth M Steinberg
- Lymphoid Malignancy Branch, National Cancer Institute, Bethesda, MD, USA
| | - Lourdes Martin-Martin
- Department of Medicine and Centro de Investigacion del Cancer (IBMCC-CSIC/USAL) and Department of Hematology, University Hospital, IBSAL and University of Salamanca, Salamanca, Spain
| | - Carmen Muñiz
- Department of Medicine and Centro de Investigacion del Cancer (IBMCC-CSIC/USAL) and Department of Hematology, University Hospital, IBSAL and University of Salamanca, Salamanca, Spain
| | - Juan Manuel Sancho
- Department of Hematology, Hospital German Trias i Puyol, University of Barcelona, Spain for the Spanish Group for the Study of CNS Disease in NHL
| | - Maria Dolores Caballero
- Department of Medicine and Centro de Investigacion del Cancer (IBMCC-CSIC/USAL) and Department of Hematology, University Hospital, IBSAL and University of Salamanca, Salamanca, Spain
| | - Marjan A Davidis
- Department of Hematology, Daniel den Hoed Cancer Center, Erasmus MC, University Medical Center Rotterdam, The Netherlands
| | - Rik A Brooimans
- Department of Medical Immunology, Daniel den Hoed Cancer Center, Erasmus MC, University Medical Center Rotterdam, The Netherlands
| | | | - Antonio Salar
- Department of Hematology, Hospital del Mar, Barcelona, Spain
| | - Eva González-Barca
- Department of Hematology, Hospital Duran i Reynals, Institut Catala d'Oncologia, IDIBELL, University of Barcelona, Spain
| | - Jose Maria Ribera
- Department of Hematology, Hospital German Trias i Puyol, University of Barcelona, Spain for the Spanish Group for the Study of CNS Disease in NHL
| | - Margaret Shovlin
- Lymphoid Malignancy Branch, National Cancer Institute, Bethesda, MD, USA
| | - Armando Filie
- Lymphoid Malignancy Branch, National Cancer Institute, Bethesda, MD, USA
| | - Kieron Dunleavy
- Lymphoid Malignancy Branch, National Cancer Institute, Bethesda, MD, USA
| | | | - Michele Spina
- Division of Medical Oncology A, National Cancer Institute, Aviano, Italy
| | - Alberto Orfao
- Department of Medicine and Centro de Investigacion del Cancer (IBMCC-CSIC/USAL) and Department of Hematology, University Hospital, IBSAL and University of Salamanca, Salamanca, Spain
| |
Collapse
|
22
|
Martinez de la Ossa A, Grebenyuk J, Mehrling T, Schaper L, Osterhoff J. High-quality electron beams from beam-driven plasma accelerators by wakefield-induced ionization injection. Phys Rev Lett 2013; 111:245003. [PMID: 24483670 DOI: 10.1103/physrevlett.111.245003] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/09/2013] [Indexed: 06/03/2023]
Abstract
We propose a new and simple strategy for controlled ionization-induced trapping of electrons in a beam-driven plasma accelerator. The presented method directly exploits electric wakefields to ionize electrons from a dopant gas and capture them into a well-defined volume of the accelerating and focusing wake phase, leading to high-quality witness bunches. This injection principle is explained by example of three-dimensional particle-in-cell calculations using the code OSIRIS. In these simulations a high-current-density electron-beam driver excites plasma waves in the blowout regime inside a fully ionized hydrogen plasma of density 5×10(17)cm-3. Within an embedded 100 μm long plasma column contaminated with neutral helium gas, the wakefields trigger ionization, trapping of a defined fraction of the released electrons, and subsequent acceleration. The hereby generated electron beam features a 1.5 kA peak current, 1.5 μm transverse normalized emittance, an uncorrelated energy spread of 0.3% on a GeV-energy scale, and few femtosecond bunch length.
Collapse
Affiliation(s)
| | - J Grebenyuk
- Deutsches Elektronen-Synchrotron DESY, D-22607 Hamburg, Germany
| | - T Mehrling
- Deutsches Elektronen-Synchrotron DESY, D-22607 Hamburg, Germany
| | - L Schaper
- Deutsches Elektronen-Synchrotron DESY, D-22607 Hamburg, Germany
| | - J Osterhoff
- Deutsches Elektronen-Synchrotron DESY, D-22607 Hamburg, Germany
| |
Collapse
|